Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
Long-term treatment of multiple sclerosis with natalizumab (NTZ) carries the risk of a devastating complication in the form of an encephalopathy caused by a reactivation of a latent John Cunningham virus infection (progressive multifocal leucoencephalopathy, PML). Early diagnosis is associated with considerably better prognosis. Quantitative EEG as an objective, rater-independent technique provides high sensitivity (88%) and specificity (82%) for the diagnosis of NTZ-PML. Combination of diagnostic modalities addressing static morphological (brain MRI) as well as functional (EEG) pathologic changes may improve risk management programmes.
KeywordsEEG Multiple sclerosis Natalizumab John Cunningham virus encephalopathy Screening Pharmacovigilance
We like to thank F. Zubler, A. Salmen, S. Dahlhaus, R. Schneider, I. Kleiter and R. Schneider-Gold for their valuable contributions to this work.
- Biogen (2017). Manufacture information. http://www.biogen-international.com. Accessed 10 Dec 2017
- Frigo, M. and Johnson, S. G. (1997). The fastest Fourier transform in the West. Massachusetts Institute of Technology, MIT-LCS-TR-728Google Scholar
- Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung H-P, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O (2014) Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:792–801CrossRefGoogle Scholar